Mylan NV (NASDAQ:MYL)

29.55
Delayed Data
As of Jan 17
 +0.29 / +0.99%
Today’s Change
26.03
Today|||52-Week Range
47.82
+7.85%
Year-to-Date
Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C
Jan 16 / Zacks.com - Paid Partner Content
Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect
Jan 10 / Zacks.com - Paid Partner Content
Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility
Jan 10 / Zacks.com - Paid Partner Content
MYL vs. SUPN: Which Stock Is the Better Value Option?
Jan 10 / Zacks.com - Paid Partner Content
INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data
Jan 10 / Zacks.com - Paid Partner Content
Is Mylan (MYL) a Great Value Stock Right Now?
Jan 08 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close29.26
Today’s open29.12
Day’s range28.75 - 29.55
Volume4,706,829
Average volume (3 months)4,974,778
Market cap$17.2B
Data as of 4:00pm ET, 01/17/2019

Growth & Valuation

Earnings growth (last year)+38.30%
Earnings growth (this year)+3.03%
Earnings growth (next 5 years)+4.00%
Revenue growth (last year)+7.06%
P/E ratio28.4
Price/Sales1.91
Price/Book1.31

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...+1.80+1.88%
INCYIncyte Corp+2.11+2.76%
ALXNAlexion Pharmaceutic...+2.92+2.61%
JAZZJazz Pharmaceuticals...-0.78-0.61%
Data as of 4:00pm ET, 01/17/2019

Financials

Next reporting dateFebruary 27, 2019
EPS forecast (this quarter)$1.42
Annual revenue (last year)$11.9B
Annual profit (last year)$696.0M
Net profit margin5.85%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
Chief Executive Officer &
Executive Director
Heather M. Bresch
President &
Executive Director
Rajiv Malik
Corporate headquarters
Hatfield, Hertfordshire

Forecasts